Overall, this exploratory liquid biopsy study revealed a strong correlation between the pretreatment levels of some metabolites and the OS of patients with metastatic stage IV melanoma treated with anti-CTL4 and/or anti-PD-1 antibodies in the first-line setting and revealed the potential of these molecules to predict outcomes and define personalized management and treatment strategies. This evidence concerns the gene SLC44A4 and melanoma.